Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11225663 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2024012598 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Universal Strategy for BBB Transport Mediated by an Inflammatory Receptor Antagonist for Neuroprotection in Ischemic Stroke.
Adv Mater
September 2025
State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.
Delivering therapeutics across the blood-brain barrier (BBB) remains a major challenge in ischemic stroke therapy. Ischemic stroke induces upregulation of various inflammatory membrane receptors on brain endothelial cells, offering potential entry points for receptor-mediated transcytosis. This study proposes a universal targeting strategy by employing inflammatory pathway antagonists as targeting ligands, which broadens the spectrum of available ligands beyond traditional receptor-binding molecules.
View Article and Find Full Text PDFEngineered Immunoagonist Non-Coding RNA (incRNA) Activates Dual TLR Pathways for Cancer Immunotherapy.
Adv Healthc Mater
September 2025
Department of Chemical Engineering, University of Massachusetts, Amherst, MA, 01003, USA.
Conventional mRNA therapeutics have focused on optimizing translation and minimizing immunogenicity for vaccine and protein replacement applications. However, immunogenicity, often considered a challenge, can also be harnessed for therapeutic advantage. This work challenges the necessity of extensive mRNA modification as a universal strategy by introducing 'immunoagonist non-coding RNA (incRNA)', a new class of RNA therapeutic that exploits innate immune activation rather than evading it.
View Article and Find Full Text PDFActivated Dendritic Cell Membrane-Engineered Nanoformulation of Metallo-Immunomodulators as Lysosome-Targeted Adjuvants for Synergistic Cancer Immunotherapy.
Adv Healthc Mater
September 2025
Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong, 999077, China.
Combination of chemotherapy and cancer immunotherapy has shown substantial clinical promise. However, the immunosuppressive tumor microenvironment (TME) poses a critical barrier to this combination therapy. Here, a tumor lysosome-targeted immunomodulatory strategy based on a biomimetic nanoadjuvant is presented, which effectively overcomes the immunosuppressive TME and demonstrates enhanced therapeutic efficacy when combined with chemotherapy.
View Article and Find Full Text PDFDiscovery of ETI41 and ETI60: novel selective endosomal Toll-like receptor inhibitors for the treatment of autoimmune diseases.
Exp Mol Med
September 2025
S&K Therapeutics, Suwon, Korea.
Endosomal Toll-like receptors (TLRs, including TLR3, TLR7, TLR8 and TLR9) play crucial roles in immune responses by recognizing pathogen-associated molecular patterns; however, their aberrant activation is implicated in inflammatory and autoimmune diseases. Developing endosomal TLR inhibitors against autoimmune diseases is clinically essential. Here we synthesized and optimized a series of compounds based on a candidate structure.
View Article and Find Full Text PDFActivation of the TLR2/NF-κB signaling axis by capsid proteinVP1 of feline calicivirus promotes IL-1β expression in vitro.
Vet Microbiol
October 2025
College of Veterinary Medicine, Jilin Agricultural University, Changchun 130118, China. Electronic address:
Feline calicivirus (FCV) induces systemic inflammation in felines, posing a serious threat to feline health worldwide. Severe cases may lead to chronic stomatitis and other inflammatory conditions. However, the precise mechanisms underlying FCV-induced inflammation remain unclear.
View Article and Find Full Text PDF